dc.contributor.author | Koyutürk, Meral | |
dc.contributor.author | Ersöz, Melike | |
dc.contributor.author | Altıok, Nedret | |
dc.date.accessioned | 2016-01-19T11:33:29Z | |
dc.date.available | 2016-01-19T11:33:29Z | |
dc.date.issued | 2007 | |
dc.identifier.citation | Koyuturk M, Ersoz M, Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett. 2007 Jun 8;250(2):220-8. doi:10.1016/j.canlet.2006.10.009 | en_US |
dc.identifier.issn | 0304-3835 | |
dc.identifier.uri | http://www.sciencedirect.com/ | en_US |
dc.identifier.uri | https://hdl.handle.net/11446/887 | en_US |
dc.description | İstanbul Bilim Üniversitesi, Tıp Fakültesi. | en_US |
dc.description.abstract | The effect of simvastatin, a widely used statin for the treatment of hypercholesterolemia, was investigated in the estrogen receptor (ER)-positive MCF-7, and the ER-negative MDA-MB 231 human breast cancer cell lines. Simvastatin induced cell cycle arrest and apoptosis in both cells. These effects of simvastatin were not altered by 17-β-estradiol treatment.
MCF-7 cells express wild-type tumor suppressor protein p53, whereas MDA-MB 231 cells carry a p53 mutation. However, no alteration in the level or localisation of p53 was observed with simvastatin treatment in either cell line. On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.identifier.doi | 10.1016/j.canlet.2006.10.009 | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | apoptosis | en_US |
dc.subject | breast cancer | en_US |
dc.subject | estrogen receptor | en_US |
dc.subject | JNK | en_US |
dc.subject | p53 | en_US |
dc.title | Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK | en_US |
dc.type | article | en_US |
dc.relation.journal | Cancer Letters | en_US |
dc.department | DBÜ, Tıp Fakültesi | en_US |
dc.identifier.issue | 2 | |
dc.identifier.volume | 250 | |
dc.identifier.startpage | 220 | |
dc.identifier.endpage | 228 | |
dc.contributor.authorID | TR140953 | en_US |
dc.contributor.authorID | TR104953 | en_US |
dc.contributor.authorID | TR188782 | en_US |
dc.relation.publicationcategory | Belirsiz | en_US |